Panacea Bio's shares jumped about 6% after the company announced that it finished enrolling participants for the late‑stage trial of its dengue vaccine, DengiAll.
Enrollment Completed
The company confirmed that 10,335 volunteers have been signed up for the Phase III trial. Each participant will be monitored for two years after receiving either the vaccine or a placebo. The trial runs at 19 sites across India.
Vaccine Overview
DengiAll is a single‑dose, tetravalent dengue vaccine. It contains weakened forms of all four dengue virus types (DEN1, DEN2, DEN3, DEN4) in one injection. If approved, it could become India’s first home‑grown dengue vaccine, with a launch target around 2027.
Share Price Reaction
Following the enrollment news, Panacea Bio’s stock rose to ₹407.60, up roughly 6% in a single session. Over the past five trading days, the share price has gained about 7%, and it’s up nearly 21% in the last month.
Long‑Term Stock Performance
- Down more than 11% over the past year.
- Up over 71% in the last five years.
- Since listing, the stock has delivered a massive 8,670% total return.
- 52‑week high: ₹581 (May 15 2025); 52‑week low: ₹282.15 (Feb 28 2025).
What This Means for Investors
The completion of enrollment shows the vaccine is moving forward on schedule, which can boost investor confidence. A successful trial could open a large market for dengue prevention in India and possibly abroad.
Disclaimer
Remember, this is perspective, not prediction. Do your own research and consider consulting a financial advisor before making any investment decisions.